Sunnyvale-Based Amarantus Closes $10M Equity Funding Facility

Sunnyvale, Calif. -- Amarantus BioSciences, a Sunnyvale-based biotechnology firm addressing an underlying form of cell death known as apoptosis, said it has closed a $10 million equity funding facility with Centurion Private Equity. The company will be able to draw down on the facility over the next 36 months in tranches of up $750,000 each. "The company intends to strategically draw down on this facility in a manner that protects the best interests of our shareholders and use the proceeds for core product development, material transactions such as licensing, mergers, acquisition and other relevant value-added business development opportunities," said Martin Cleary, the chairman and CEO of Amarantus.
http://www.amarantus.com
http://www.marketwire.com/press-release/amarantus-biosciences-announces-close-10m-equity-funding-facility-with-centurion-private-otcbb-ambs-1572738.htm